Chemoprevention is a potential strategy for reduction of breast cancer rates worldwide. However, the available pharmacological options with this purpose present several serious adverse effects, which limit women's adherence to treatment. This project aims to develop and characterize a nanostructured lipid carrier for the drug fenretinide, for subcutaneous administration in the mammary tissue, for sustained drug release and localization in the target tissue, reducing the systemic adverse effects incidence and increasing the high-risk population adherence to chemoprevention. The nanocarriers will be characterized through differential scanning calorimetry, dynamic light scattering, rheological behavior and scanning microscopy. The drug release kinetics will be evaluated in vitro and the irritation potential will be studied through the HET-CAM method, which is alternative to the use of animals. Selected formulations will have its localization evaluated in vivo to verify if they concentrate in the mammary tissue.
News published in Agência FAPESP Newsletter about the scholarship: